Schwarz DA, Katayama CD, Hedrick SM. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity. 1998;9:657–68.
Article
CAS
PubMed
Google Scholar
Liu F, Zhou P, Wang Q, Zhang M, Li D. The Schlafen family: complex roles in different cell types and virus replication. Cell Biol Int. 2017. doi:10.1002/cbin.10778.
Google Scholar
Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA. 2012;109:15030–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012;491:125–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2016;7:3084–97.
Article
PubMed
Google Scholar
Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol. 2007;27:5806–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–9.
Article
CAS
PubMed
Google Scholar
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179–204.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murai J, Huang SN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Murai J, Huang S-YN, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13:433–43.
Article
CAS
PubMed
Google Scholar
Murai J, Feng Y, Yu GK, Ru Y, Tang S-W, Shen Y, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534–50.
PubMed
PubMed Central
Google Scholar
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Article
CAS
PubMed
Google Scholar
Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273–80.
Article
CAS
PubMed
Google Scholar
NCCN. Clinical practice guidelines in oncology. Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143:3–15.
Article
PubMed
PubMed Central
Google Scholar
Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.
Article
PubMed
Google Scholar
Lloyd KL, Cree IA, Savage RS. Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer. 2015;15:117.
Article
PubMed
PubMed Central
Google Scholar
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJS, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.
Article
CAS
PubMed
Google Scholar
Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
Article
PubMed
PubMed Central
Google Scholar
Jeronimo C, Forget D, Bouchard A, Li Q, Chua G, Poitras C, et al. Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Mol Cell. 2007;27:262–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6:e1253654.
Article
PubMed
PubMed Central
Google Scholar
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
CAS
PubMed
PubMed Central
Google Scholar
Zoppoli G, Brohee S, Desmedt C, Sotiriou C, Ballestrero A. Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma. J Immunother Cancer. 2015;3:O3. doi:10.1186/2051-1426-3-S1-O3.
Article
PubMed Central
Google Scholar
Gendoo DMA, Ratanasirigulchai N, Schroder MS, Pare L, Parker JS, Prat A, et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2016;32:1097–9.
Article
CAS
PubMed
Google Scholar
Abdi H, Valentin D. Multiple correspondence analysis. In: Encyclopedia of measurement and statistics. Thousand Oaks: SAGE Publications, Inc.; 2007. p. 651–7. doi:10.4135/9781412952644. NV-3.
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
Article
PubMed
PubMed Central
Google Scholar
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15(1):68–74. doi:10.1038/nm.1908.
Article
CAS
PubMed
Google Scholar
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518–27. doi:10.1038/nm1764.
Article
CAS
PubMed
Google Scholar
Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.
Article
PubMed
Google Scholar
Bosman FT, Yan P, Tejpar S, Fiocca R, Van Cutsem E, Kennedy RD, et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res. 2009;15:5528–33.
Article
CAS
PubMed
Google Scholar
Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104:1635–46.
Article
CAS
PubMed
Google Scholar
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJ, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Deng Y, Cai Y, Huang Y, Yang Z, Bai Y, Liu Y, et al. High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. BMC Cancer. 2015;15:833.
Article
PubMed
PubMed Central
Google Scholar
Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathol. 2013;26:825–34.
Article
CAS
Google Scholar